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Background: Hashimoto’s encephalopathy is a poorly understood syndrome consisting of heterogeneous
neurological symptoms and high serum antithyroid antibody titers, typically responding to steroids. More clinical
series studies are required to characterize the clinical, laboratory and imaging features, and outcomes, especially in
the Chinese population.
Methods: We analyzed the clinical, laboratory, and imaging features and outcomes of thirteen consecutive patients
with Hashimoto’s encephalopathy diagnosed in Xuan Wu Hospital, Beijing from 2005 to 2010 retrospectively.
Results: Cognitive impairment (84.6%) and psychiatric symptoms (38.5%) were the most frequent symptoms.
Seizures (30.8%) and myoclonus (7.7%) were less common than previously described. Three (23.1%) patients
showed abnormal signals in hippocampus or temporal lobe, which were believed related to their memory
disorders or seizures. MRI changes showed resolution paralleling clinical improvement in one patient. Among eight
patients who received steroid therapy, five patients recovered, one patient improved with residual deficits, and two
patients relapsed or had no effect. Among five non-steroid treated patients, three patients experienced
stable remission with antiepileptic drugs or general neurotrophic therapy, and two patients experienced
continuous deterioration.
Conclusions: Most patients with Hashimoto’s encephalopathy showed good response to steroids. Some patients
improved without steroid therapy. Considering its reversible course, we recommend that Hashimoto’s
encephalopathy should always be in the differential diagnosis while evaluating disorders of the central
nervous system.Background
Hashimoto’s encephalopathy (HE), also known as
steroid-responsive encephalopathy associated with auto-
immune thyroiditis (SREAT) [1], is a rare neurological
syndrome that is poorly understood and often misdiag-
nosed. The first case was described by Lord Brain in
1966, in which a patient with Hashimoto thyroiditis
(HT) showed impairment of consciousness, tremor, cog-
nitive loss and stroke-like episodes [2]. The clinical man-
ifestations of HE include cognitive impairment, transient
aphasia, tremor, myoclonus, ataxia, seizure, sleep dis-
turbance and headache, with fluctuating symptoms in
95% of patients [1]. Two subtypes were proposed: a* Correspondence: jiaxuanwu@126.com
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reproduction in any medium, provided the orvasculitic type with stroke-like episodes and a diffuse,
progressive type with insidious onset but progressive de-
terioration of mental functions [3]. HE is generally con-
sidered to be an autoimmune encephalopathy. However,
the pathogenesis is still not clear. Anti-thyroid peroxid-
ase antibody (TPO-Ab), present in almost all HE cases
[4], can also be found in general population with euthyr-
oid status [5]. A direct causal relationship between thy-
roid antibodies and HE seems unlikely [3].
The first set of diagnostic criteria for HE was put for-
ward by Peschen-Rosin and co-workers in 1999, which
encompassed unexplained episodes of relapsing myo-
cloni, generalized seizures, focal neurological deficits or
psychiatric disorders, and at least 3 of the following: ab-
normal EEG, elevated thyroid antibodies, elevated CSF
protein and/or oligoclonal bands, excellent response to
steroids, unrevealing cerebral MRI [6]. After that, the
knowledge of symptoms of HE was much more widened.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients [7-10]. Although the role in the pathogenesis of
HE is still debated, it can’t be ignored that the elevation
of anti-thyroid antibodies was observed in all HE
patients. Therefore, the following principles were
included in the diagnostic criteria by majority of
researchers [1,7,8]: the elevated serum antithyroid anti-
bodies; neurological illness mostly presented as clouding
of consciousness, cognitive impairment, seizures, myo-
clonus, ataxia, psychiatric symptoms and focal neuro-
logical deficits; exclusion of infectious, toxic, metabolic,
vascular or neoplastic etiologies.
Because of the low prevalence (about 2.1/100 000)
[11], varied clinical features, unclear pathogenesis and
histopathologic characteristics [1,8,12], currently no
recognized diagnostic criteria for HE have been estab-
lished. Therefore, more clinical series studies are
required to characterize the clinical, laboratory and im-
aging features, and outcomes of HE patients. To our
knowledge, there has been no published series report of
HE from Asia yet. In this study, we try to characterize
the clinical features and outcomes of a series of Chinese
HE cases in whom the diagnosis of HE was made at
Xuan Wu Hospital (in Beijing) between 2005 and 2010.
The inclusion criteria for this study are: (1) encephalop-
athy manifested by clouding of consciousness, cognitive
impairment, seizures or neuropsychiatric features; (2)
elevated anti-TPO antibody with euthyroid status (serum
sensitive thyroid-stimulating hormone [TSH], 0.35–
5.5 uIU/ml); (3) no alternative infectious, toxic, meta-
bolic, vascular or neoplastic etiology related to the
neurological symptoms in blood, urine, cerebrospinal
fluid (CSF) or neuroimaging examinations.
Methods
This retrospective study received approval from the Xuan
Wu Hospital institutional review board. We searched the
electronic medical record system to identify and review
patients diagnosed with HE at Xuan Wu Hospital (in Bei-
jing) between 2005 and 2010, using the following criteria:
(1) encephalopathy manifested by clouding of conscious-
ness, cognitive impairment, seizures or neuropsychiatric
features; (2) elevated anti-TPO antibody with euthyroid
status (serum sensitive thyroid-stimulating hormone
[TSH], 0.35–5.5 uIU/ml); (3) no alternative infectious,
toxic, metabolic, vascular or neoplastic etiology related to
the neurological symptoms in blood, urine, cerebrospinal
fluid (CSF) or neuroimaging examinations. We did not
include steroid response as a criterion because not all HE
patients respond to corticosteroid therapy [7,8,10]. Sec-
ond, corticosteroids were not the standard therapy for HE
in our institution before 2008, and some patients were
unwilling to take the risks of steroid therapy. These
patients provided the opportunity to observe the clinicalcourse of HE without steroid therapy. Furthermore, ele-
vated serum anti-TPO antibody was included as a diag-
nostic criterion for its much higher prevalence in HE
patients than anti-thyroglobulin (anti-TG) antibody
[1,4,8].
After identification of patients, demographic, clinical,
laboratory, imaging data and treatment responses were
collected. Furthermore, we followed up all patients and
present the long-term clinical course of HE.
Results
Demographic and clinical data
Thirteen patients were identified. The mean age at onset
was 42 years (range, 21 to 63 years), and 10 were female.
Three patients had a history of thyroid disorders. One
patient had systemic lupus erythematosus, and another
had Raynaud’s syndrome. Eleven patients (84.6%) had
been misdiagnosed as other disorders, including stroke
or transient ischemic attack (23.1%), demyelinating dis-
ease (15.4%), viral encephalitis (15.4%), mitochondrial
encephalopathy (7.7%), essential tremor (7.7%), Alzhei-
mer’s disease (7.7%), and paraneoplastic neurological
syndrome (7.7%). Clinical presentations are summarized
in Table 1. The most common symptom was cognitive
impairment (11 patients, 84.6%). Among these patients,
9 had complaints of cognitive deficits (Patients No. 1, 4,
5, 6, 8, 10, 11, 12, and 13), which had been confirmed by
objective examination, and 2 were found to have cogni-
tive impairments through neurological examination
(Patients No. 3 and 7). The memory impairment was the
predominant symptom in majority of these patients
(Patients No. 1, 4, 5, 8, 10, 11 and 13), and others had
multiple cognitive domains impairment (Patients No. 3,
6, 7 and 12), including memory, calculation, orientation
and language. The cognitive abilities of these patients
were evaluated by at least one cognitive scale (Table 1),
including the Mini-Mental State Examination (MMSE)
[13], the Clinical Memory Scale (CMS) [14] and the
Wechsler Adult Intelligence Scale-Revise Chinese
(WAIS-RC) [14], except for patient No. 6, who could
not cooperate with the detailed cognitive tests on admis-
sion. Other common symptoms included psychiatric
symptoms (5 patients, 38.5%), seizures (4 patients,
30.8%) and sleep disturbance (4 patients, 30.8%). Three
patients (23.1%) manifested with stroke-like episodes.
Dizziness and headache were each present in 2 (15.4%)
patients. Myoclonus, ataxia or gait disorder, tremor,
aphasia and lateralized sensory deficit, were all less com-
mon (1 patient each, 7.7%).
Serologic and CSF studies
The upper detectable limits of anti-TPO antibody and
anti-TG antibody tests in our institution were 1300 U/ml
and 500 U/ml respectively. Test values higher than the




















1 F 52 19 months Memory impairment,
psychiatric symptoms,
insomnia
MMSE, 21 TPO>1300 + + Levothyroxine 22 No improvement
TG>500
2 F 32 6 months Generalized seizures TPO>1300 + − ++ Antiepileptic treatment 12 No further seizures
TG>500





MMSE, 20 TPO 831.9 + − ++ Intravenous
methylprednisolone
500 mg for
3 d followed by oral
prednisone taper
TP 492.0 13 Two stroke-like
episodes
TG 41.9 TG 0.7
4 M 27 3 weeks Memory impairment MMSE, 25 TPO>1300 + + − Nerve growth factor,
vitamin B12
15 Return to normal
cognitive function,
MMSE, 30TG 38.8




CMS, 47 TPO 519.1 − + Intravenous
methylprednisolone
1 g for 5 d
20 No improvement
TG 114.7





TPO 557.8 − + − Intravenous
methylprednisolone
1 g for 5 d
followed by oral
prednisone taper
TP 273.8 22 Complete remission,
no further stroke-like
episodeTG 44.3 TG 0.2
7 M 63 7 days Acute headache,
multiple cognitive
domains impairment
MMSE, 17 TPO>1300 − + + Intravenous
methylprednisolone




8 F 43 2 months Ataxia, memory
impairment, seizures
MMSE, 19 TPO >1300 + − ++ Intravenous
methylprednisolone




9 F 21 2 months Generalized seizures TPO >1300 + + ++ Antiepileptic drugs 9 No further seizures
TG 37.9




CMS, 72 TPO 139.6 − + Intravenous
methylprednisolone








11 F 37 2 years Memory impairment,
tremor




























Table 1 Clinical findings and treatment outcomes of 13 patients with Hashimoto’s Encephalopathy (Continued)




MMSE, 9 TPO >1300 + + + Intravenous
dexamethasone,











WAIS-RC, 84 TPO >1300 + + + Intravenous
methylprednisolone
500 mg for 5 d
followed by oral
prednisone taper
TPO 1144.8 18 Complete remission,
no further stroke-like
episodeTG 45.6 TG 48.4
Abbreviations: TPO, thyroid peroxidase; TG, thyroglobulin; MMSE, Mini-Mental State Examination; CMS, Clinical Memory Scale; WAIS-RC, Wechsler Adult Intelligence Scale-Revise Chinese; MRC, Medical Research Council.


















Table 2 Laboratory findings of 13 patients with
Hashimoto’s Encephalopathy
Test Number (%) of patients/total
number of patients tested
Serologic findings
Anti-TPO antibody elevated 13 (100)/13
Anti-TG antibody elevated 6 (46.2)/13
Aminotransferase level elevated 5 (38.5)/13
gG level reduced 3 (23.1)/13
Complement C3 level reduced 3 (23.1)/13
ANA positive 2 (28.6)/7
ENA antibody positive 2 (18.2)/11
Anti-SSA antibody 1 (9.1)/11
Anti-Jo-1 antibody 1 (9.1)/11
C reactive protein level elevated 1 (7.7)/13
Rheumatoid factor positive 1 (7.7)/13
CSF
Protein levels elevated 8 (61.5)/13
Myelin basic protein levels elevated 3 (33.3)/9
gG synthesis rate elevated 3 (33.3)/9
Oligoclonal bands positive 1 (11.1)/9
Abbreviations: TPO, thyroid peroxidase; TG, thyroglobulin; ESR, erythrocyte
sedimentation rate; ANA, antinuclear antibody; ENA, extractable nuclear
antigen; ANCA, anti-neutrophil cytoplasmic antibody; ACL, anticardiolipin.
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the present study. By definition, elevated TPO-Ab (average,
1057.6 U/ml; range, 139.6–1300 U/ml; normal reference
range, 0–60 U/ml) and euthyroid status were observed in
all patients. The serum level of anti-TG antibody was ele-
vated in 6 (46.2%) patients (average, 133.7 U/ml; range,
24.2–500 U/ml; normal reference range, 0–60 U/ml). No
CSF pleocytosis was observed. The CSF protein level was
elevated in 8 (61.5%) patients (average, 50.4 mg/dl; range,
22–146 mg/dl; reference range, 15–45 mg/dl). Other sero-
logic and CSF findings were given in Table 2.Figure 1 MRI scans of HE patients. (A and B) Patient No.4 with memory
abnormalities are believed to be responsible for the memory impairment.Electroencephalogram (EEG)
EEG was tested in 10 patients. Three (30%) were normal;
4 (40%) had epileptiform abnormalities (Patients No. 2,
3, 8 and 9) and 3 (30%) showed generalized slowing
(Patients No. 7, 12 and 13).Magnetic resonance imaging (MRI)
All 13 patients underwent brain MRI examination. Four
(30.8%) patients (Patients No. 2, 3, 8 and 11) had normal
results. Nonspecific abnormal signals in white matter
were noted in 6 (46.2%) patients (Patients No. 1, 5, 6, 7,
12 and 13). One (7.7%) patient (Patient No. 5) had cere-
bral atrophy. Three (23.1%) patients (Patients No. 4, 9
and 10) had hippocampus, temporal lobe or splenium
corporis callosi abnormal signals (Figure 1), which were
believed related to their memory disorders or seizures.
One patient (Patient No. 6) showed complete resolution
in MRI follow-up.Treatment and follow-up
We followed up all 13 patients (average, 14.5 months;
range, 9–25 months). The detailed treatments, responses
and related data were given in Table 1.
Among the 8 patients (61.5%) who received cortico-
steroid therapy, 5 (62.5%) had complete remission; 1
(12.5%) had partial improvement; 1 (12.5%) had relapses,
and 1 (12.5%) had no response in our follow-up. Serum
levels of antithyroid antibodies were reduced in all the 3
patients retested after corticosteroid treatment. The out-
comes of steroid treatment were not associated with the
serum levels of antithyroid antibodies, while patients
who received early treatment were more likely to have
complete remission, especially for patients with stroke-
like episodes. For patients whose symptoms persisted for
a long time before steroid therapy, it seemed difficult to
get significant improvement.impairment. The splenium corporis callosi and bilaterial hippocampal
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with seizures were treated with antiepileptic drugs and
had no further epileptic attacks over 12 and 9 months of
follow up. No improvement was observed in 1 patient
treated with levothyroxine. With general neurotrophic
therapy, including nerve growth factor and vitamin B12,
complete remission was observed in 1 patient and con-
tinued deterioration in the other patient.
Discussion
HE has attracted growing attention in the last 10 years.
This is partly due to its treatability and unclear patho-
genesis. In China, HE is still an under recognized en-
tity because of its various clinical manifestations and
absence of specific biomarkers. In this retrospective
study, by analyzing the clinical, laboratory, imaging
features and outcomes of 13 Chinese HE patients, we
try to provide more characterization of HE, especially
in Chinese patients.
The clinical symptoms of our patients are quite varied.
Cognitive impairment and psychiatric symptoms are
among the most common symptoms. However, the fre-
quency of seizures and myoclonus showed a big differ-
ence from previous reports. In the review by Ferracci
et al., seizures and myoclonus are among the most fre-
quent events in all 121 reported HE patients [7]. In
other two studies, seizures and myoclonus are also
ranked as common symptoms [1,8]. In our study, sei-
zures were observed in 4 patients and myoclonus was
observed in only 1 patient. Due to the various clinical
manifestations, initial alternative diagnoses are not sur-
prising. The most common misdiagnoses were ischemic
cerebrovascular disease, demyelinating disease and viral
encephalitis. Interestingly, unlike the study by Castillo
et al. [1], neurodegenerative diseases, including
Creutzfeldt-Jakob disease and Alzheimer’s disease, were
not frequently considered.
Various neuroimaging features have been reported in
HE. MRI may show normal, diffuse cortical atrophy or
localized increased T2 signal [7,15]. In this study, most
patients had normal MRI or nonspecific abnormalities.
In one patient with MRI follow-up, MRI changes showed
resolution paralleling clinical improvement. Interestingly,
3 (23.1%) patients with memory disorders or seizures
showed abnormal signals in hippocampus or temporal
lobe. Instead of providing direct evidence for diagnosis,
neuroimaging studies in HE patients are more important
for exclusion of other possible neurological disorders.
Currently, steroid therapy is considered the first choice
for HE patients if there are no contraindications [7].
Some researchers include a beneficial response to gluco-
corticoid therapy as a criterion for the diagnosis of HE
[1]. In this study, among 8 patients who received steroid
therapy, 5 patients recovered, 1 patient improved withresidual deficits, and 2 patients relapsed or had no effect.
It is worth noting that among 5 non-steroid treated
patients, 3 patients showed stable remission with antie-
pileptic drugs or general neurotrophic therapy. The true
efficacy of steroids remains uncertain without a treat-
ment trial, which is extremely difficult in rare diseases
like HE.
The pathogenic mechanism of HE is unknown. The
histologic finding of perivascular lymphocytic infiltration
[16], and the response to steroid and other immunomodu-
latory therapies suggests an autoimmune disorder. Some
evidences support the hypothesis of autoimmune vascu-
litis. The SPECT study showed focal or generalized hypo-
perfusion which might be produced by vasculitic
disruption of cerebral microvasculature [17]. Pathological
study demonstrated perivascular lymphocytic infiltration
[16]. More important, an autoantigen, α-enolase, was
identified in HE patients, but not in the HT and normal
controls [18,19]. α-enolase is an antigen of the thyroid and
brain. It is concentrated in endothelial cells. However, the
vasculitic hypothesis met many challenges, especially
negative pathological findings in some HE patients
[20,21]. Elevated antithyroid antibodies are generally con-
sidered necessary for the diagnosis. However, different
from other autoimmune neurological disorders such as
myasthenia gravis in which autoantibodies have definite
mechanism [22], the role of antithyroid antibodies in the
pathogenesis of HE is still not clear. Recently, Blanchin
et al. reported that anti-TPO antibody from HE patients
were able to bind cerebellar astrocytes in HE patients but
not in HT patients [23]. This may support the role of anti-
TPO antibody in the pathogenesis of HE. However, con-
sidering its wide presence in population [24], more inves-
tigations are needed to prove the pathogenic role of anti-
TPO antibody.
The term “Hashimoto’s encephalopathy” was first put
forward by Lord Brian in 1966 [2]. Since there is no evi-
dence that antithyroid antibodies have a role in patho-
genesis, this term could be misleading. Some
investigators proposed the term “steroid-responsive en-
cephalopathy associated with autoimmune thyroiditis
(SREAT)” [1] to replace “Hashimoto’s encephalopathy”.
However, not all HE patients respond to corticosteroid
therapy [7,8,10]. It also seems inappropriate to name a
disorder with treatment response to a nonspecific ther-
apy. Therefore, as Drs. Chong and Rowland noted:
“Until the pathogenesis is understood, the eponym
(Hashimoto’s Encephalopathy) seems to be the most ap-
propriate name for the condition because it links the
only known identifier, a high serum concentration of
antithyroid antibodies, to the encephalopathy” [8].
Our study has several limitations. First, some HE
patients, who showed good response to steroids, were
not included due to lack of CSF studies. Second, not all
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these patients also provide us with an opportunity to ob-
serve the clinical course of HE without steroid therapy.
Third, data presented here are mostly clinical observa-
tions. None of these 13 patients underwent brain biopsy.
Conclusions
This study summarized the clinical, laboratory, imaging
features and outcomes of 13 Chinese HE patients. Most
patients showed good response to steroids. Some
patients improved without steroid therapy. Considering
its reversible course, we recommend that HE should al-
ways be in the differential diagnosis while evaluating dis-
orders of the central nervous system.
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